• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, June 17, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Company updates & acquisitions

EssilorLuxottica continues momentum with strong 2023 financials

by Myles Hume
February 20, 2024
in Company updates & acquisitions, Local, News, Ophthalmic insights, Ophthalmic organisations, Optometry networks
Reading Time: 3 mins read
A A
Asia-Pacific saw strong growth in 2024 for EssilorLuxottica.  Image: EssilorLuxottica.

Asia-Pacific saw strong growth in 2024 for EssilorLuxottica. Image: EssilorLuxottica.

Share on FacebookShare on Twitter

Asia-Pacific was EssilorLuxottica’s best performing region in terms of sales growth in 2023, in a year when the world’s largest optical group exceeded 7% revenue growth for a third consecutive time and posted a net profit of €2.9 billion (AU$4.8 b).

The company also posted its Q4 financial results, where Asia-Pacific revenue was up 10.3% (at constant exchange rates) on the comparable 2022 quarter. Notably, EssilorLuxottica saw “continued positive pace” across its 402 OPSM stores, while Sunglass Hut saw negative grow in Australia, but was strong in the rest of the region.

The group’s board met on 14 February 2024 to approve the consolidated financial statements for the year ended 31 December 2023, in results that chairman and CEO Mr Francesco Milleri and deputy CEO Mr Paul du Saillant said they were “proud to share”.

“These strong results … have delivered another year above 7% revenue growth, including an acceleration in Q4, with every one of our regions doing its part,” they said.

“Our profitability remained strong, with a record adjusted group net profit close to €3 billion (AU$4.8 b) and free cash flow at €2.4 billion (AU$4 b). It was also a year of major investments: growing new product categories, with Stellest in myopia and Ray-Ban Meta in wearables, adding beloved brands like Moncler and Jimmy Choo to our portfolio, leveraging artificial and business intelligence, expanding our operations footprint and reinforcing the retail presence globally. This will support the evolution of the company and the transformation of the industry over the next decade.”

After three years of strong results, the board unanimously agreed to distribute a dividend of €3.95 (AU$6.51) per share.

In 2023, Asia-Pacific recorded more than €3 billion (AU$4.9 b) in revenue, which was 14.3% more than the year prior (at constant exchange rates). The Professional Solutions business – which supplies lenses, frames and equipment to optical businesses – was the strongest contributor with almost €2.1 billion (AU$3.5 b) in revenue in the region, with Direct to Consumer – such as OPSM, Sunglass Hut and other storefronts – delivering nearly €950 million (AU$1.6 b).

It’s hoped Nuance Audio will eliminate the psychological barrier with traditional hearing aids. Image: Havas Red.

In other updates from the past 12 months, EssilorLuxottica lauded the debut of its Nuance Audio concept at the Consumer Electronics Show in Las Vegas. The technology integrates an open-ear hearing solution into eyewear and is being touted as a disruptor “that bridges two industries combining good vision and better hearing”.

“We also progressed on our sustainability roadmap, Eyes on the Planet, reaching carbon neutrality in Europe and continuing our journey to connect our communities around the world with a common culture and shared values, growing our employee shareholders globally to almost 80,000,” EssilorLuxottica stated.

“With all these positive results and momentum, we are confident that we will keep the pace and meet our long-term targets.”

More reading

EssilorLuxottica reveals Nuance Audio integrating open-ear hearing technology into eyewear

EssilorLuxottica to acquire EyeQ Optometrists

OPSM introduces remote optometry consultations

Related Posts

The brand is renowned for “signature artisanal craftsmanship and precise engineering”. Image: Safilo.

Safilo launches Stuart Weitzman eyewear in Australia

by Staff Writer
June 17, 2025

Stuart Weitzman has expanded its global luxury brand footprint with a first eyewear collection available to Australian independent optical practices...

Studies show only about 17% of people are currently wearing lenses truly matching their visual sensitivity. Image: Rodenstock.

Understanding the concept of ‘visual sensitivity’

by Staff Writer
June 17, 2025

Even when a lens is designed identically for two different people, they can have a polarising visual experience. ALEX RIGBY...

The Eyerising device is reported to be the only red-light device with international regulatory approval outside of China. Image: Eyerising International.

Inclusion of red-light therapy in WSPOS 2025 Myopia Consensus Statement

by Myles Hume
June 16, 2025

Repeated low-level red-light (RLRL) therapy has been included in the 2025 Myopia Consensus Statement released by the World Society of...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited